Acute Pancreatitis News and Research RSS Feed - Acute Pancreatitis News and Research

Acute pancreatitis is a sudden inflammation of the pancreas. Depending on its severity, it can have severe complications and high mortality despite treatment. While mild cases are often successfully treated with conservative measures, such as NPO (nil by mouth or NBM) and IV fluid rehydration, severe cases may require admission to the ICU or even surgery (often requiring more than one intervention) to deal with complications of the disease process.
Research shows CRAC channel inhibitors decrease lesion size, brain hemorrhage, and neurological deficits in TBI model

Research shows CRAC channel inhibitors decrease lesion size, brain hemorrhage, and neurological deficits in TBI model

Researchers from the San Francisco Veterans Affairs Medical Center and UCSF, and CalciMedica, Inc., are presenting a poster at the 46th annual Society for Neuroscience meeting in San Diego describing the use of calcium release-activated calcium (CRAC) channel inhibitors in traumatic brain injury (TBI). [More]
Mild to moderate rise in blood fats increases risk of developing acute pancreatitis

Mild to moderate rise in blood fats increases risk of developing acute pancreatitis

New research from the University of Copenhagen shows that mild to moderate levels of blood fats equals an increased risk developing acute pancreatitis. It is far more serious than we previously believed it to be, according to the professor behind the study. [More]
Loyola specialists cure patient’s acute pancreatitis

Loyola specialists cure patient’s acute pancreatitis

Larry Jacob got the call every parent fears. His daughter was sick, away at college and needed help. Mr. Jacob left his home in the Chicago suburbs and was driving to Western Illinois University when he suddenly doubled over in pain. [More]
Study identifies risk factors for asparaginase-induced pancreatitis in ALL patients

Study identifies risk factors for asparaginase-induced pancreatitis in ALL patients

Researchers have identified a rare genetic variation associated with a dramatically increased risk of severe acute pancreatitis in acute lymphoblastic leukemia (ALL) patients treated with the chemotherapy agent asparaginase. St. Jude Children's Research Hospital led the study, which appears today in the Journal of Clinical Oncology. [More]
Disease burden, health care costs higher in children with recurrent acute and chronic pancreatitis

Disease burden, health care costs higher in children with recurrent acute and chronic pancreatitis

The burden of recurrent acute and chronic pancreatitis in children may be higher than previously thought, with high costs related to repeated hospitalizations, report a pair of studies in the Journal of Pediatric Gastroenterology and Nutrition. [More]
Gallstones, statins increase risk of acute pancreatitis, shows study

Gallstones, statins increase risk of acute pancreatitis, shows study

Idiopathic pancreatitis is often caused by small gallstones that are difficult to observe prior to surgery, shows a study from the University of Eastern Finland. Small gallstones were found in surgery from two out of three idiopathic pancreatitis patients. [More]
Lund University researchers reveal how the body develops acute pancreatitis

Lund University researchers reveal how the body develops acute pancreatitis

Researchers at Lund University in Sweden may have discovered one of the keys to understanding how the body develops acute pancreatitis. The results offer hope for the development of drugs that specifically target the disease. [More]
New paper describes positive effects of CRAC channel inhibitors in animal models of acute pancreatitis

New paper describes positive effects of CRAC channel inhibitors in animal models of acute pancreatitis

Researchers from CalciMedica, Inc. and the University of Liverpool today announced the publication of a paper describing positive effects of calcium release-activated calcium (CRAC) channel inhibitors in animal models of acute pancreatitis. The paper, titled "Inhibitors of ORAI1 prevent cytosolic calcium-associated injury of human pancreatic acinar cells and acute pancreatitis in 3 mouse models" appears in the August edition of the journal Gastroenterology. [More]
Glucose-control drug sitagliptin does not raise risk of cardiovascular events

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events. [More]
FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. [More]
Short-term use of DPP-4 inhibitors does not increase risk for pancreatic cancer

Short-term use of DPP-4 inhibitors does not increase risk for pancreatic cancer

Researchers at the UNC Gillings School of Global Public Health and the UNC School of Medicine have found that a popular class of diabetes medications called DPP-4 inhibitors does not increase the short-term risk of pancreatic cancer, as was previously reported by other researchers. [More]
Insulin can protect cells of pancreas from acute pancreatitis

Insulin can protect cells of pancreas from acute pancreatitis

Scientists from The University of Manchester have discovered that insulin can protect the cells of the pancreas from acute pancreatitis - a disease for which there is currently no treatment. [More]
PET-CT using FDG-labeled leucocytes may help in detecting infection in patients with acute pancreatitis

PET-CT using FDG-labeled leucocytes may help in detecting infection in patients with acute pancreatitis

A new study diagnosing infection in patients with pancreatic fluid collections may swiftly and accurately rule out active infection in the body. [More]
GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S. [More]
Isis Pharmaceuticals reports final data from ISIS-APOCIIIRx Phase 2 study in patients with FCS

Isis Pharmaceuticals reports final data from ISIS-APOCIIIRx Phase 2 study in patients with FCS

Isis Pharmaceuticals, Inc. announced the final data from its Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with familial chylomicronemia syndrome, or FCS. [More]
FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [More]

Mayo Clinic collaborates with Enterprise Ireland to advance novel medical technologies

Mayo Clinic today announced a five-year collaboration with Enterprise Ireland, the Irish enterprise development agency, to advance novel medical technologies originating from Mayo Clinic. [More]
Researchers find link between acute pancreatitis and pancreatic cancer

Researchers find link between acute pancreatitis and pancreatic cancer

In a study published in Clinical Gastroenterology and Hepatology, Saint Louis University researchers have found a link between acute pancreatitis (inflammation of the pancreas) and pancreatic cancer, a finding which may eventually lead to some pancreatic cancers being detected earlier. [More]
FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

AstraZeneca and Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommends the investigational medicine metreleptin for the treatment of pediatric and adult patients with generalized lipodystrophy (LD). [More]
FDA approves Prior Approval Supplement for EMBEDA Extended Release Capsules CII

FDA approves Prior Approval Supplement for EMBEDA Extended Release Capsules CII

Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved a Prior Approval Supplement for EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII. [More]
Advertisement
Advertisement